GRN and Alzheimer disease: Given the genetic risks associated with low progranulin levels in FTD and AD, increasing brain levels of progranulin via recombinant protein, viral delivery, or small molecule regulators, have all been proposed as potential disease treatments (reviewed in Gass et al., 2012).